The long and winding road for overcoming resistance to hormone therapy in breast cancer

The long and winding road for overcoming resistance to hormone therapy in breast cancer Breast Cancer (2018) 25:377–378 https://doi.org/10.1007/s12282-018-0876-2 SPECIAL FEATURE Resistance to hormonal therapy The long and winding road for overcoming resistance to hormone therapy in breast cancer Shigehira Saji Published online: 28 May 2018 © The Japanese Breast Cancer Society 2018 Endocrine therapy is a main modality for hormone receptor useful for stopping the motor driven car, and for avoiding a (HR)-positive breast cancer. In the treatment of advanced restart by engine. Endocrine therapy should be accompanied or metastatic HR-positive breast cancer (ABC/MBC), endo- with it. crine therapy is generally used as sequential therapy, which In this special feature issue of Breast Cancer, three arti- uses a single drug one by one when the disease progresses. cles reported recent progress of this topic. Hanamura et al. Although this is due to consistent dependency on the described a potential endocrine resistance mechanism in estrogen receptor (ER) system in HR-positive breast can- breast cancer found via cell studies and animal models [3]. cer, in later periods of ABC/MBC treatment, tumors gradu- They established six types of aromatase inhibitor-resistant ally lose the response to this type of endocrine drugs. Many breast cancer cell lines, and showed us an important issue drugs have been developed to date, and recent progress where a http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Breast Cancer Springer Journals

The long and winding road for overcoming resistance to hormone therapy in breast cancer

Loading next page...
 
/lp/springer_journal/the-long-and-winding-road-for-overcoming-resistance-to-hormone-therapy-8wZfzYxvXd
Publisher
Springer Journals
Copyright
Copyright © 2018 by The Japanese Breast Cancer Society
Subject
Medicine & Public Health; Surgical Oncology; Oncology; Surgery; Cancer Research
ISSN
1340-6868
eISSN
1880-4233
D.O.I.
10.1007/s12282-018-0876-2
Publisher site
See Article on Publisher Site

Abstract

Breast Cancer (2018) 25:377–378 https://doi.org/10.1007/s12282-018-0876-2 SPECIAL FEATURE Resistance to hormonal therapy The long and winding road for overcoming resistance to hormone therapy in breast cancer Shigehira Saji Published online: 28 May 2018 © The Japanese Breast Cancer Society 2018 Endocrine therapy is a main modality for hormone receptor useful for stopping the motor driven car, and for avoiding a (HR)-positive breast cancer. In the treatment of advanced restart by engine. Endocrine therapy should be accompanied or metastatic HR-positive breast cancer (ABC/MBC), endo- with it. crine therapy is generally used as sequential therapy, which In this special feature issue of Breast Cancer, three arti- uses a single drug one by one when the disease progresses. cles reported recent progress of this topic. Hanamura et al. Although this is due to consistent dependency on the described a potential endocrine resistance mechanism in estrogen receptor (ER) system in HR-positive breast can- breast cancer found via cell studies and animal models [3]. cer, in later periods of ABC/MBC treatment, tumors gradu- They established six types of aromatase inhibitor-resistant ally lose the response to this type of endocrine drugs. Many breast cancer cell lines, and showed us an important issue drugs have been developed to date, and recent progress where a

Journal

Breast CancerSpringer Journals

Published: May 28, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off